| Autor: |
Johannes, Jeffrey W., Balazs, Amber Y. S., Barratt, Derek, Bista, Michal, Chuba, Matthew D., Cosulich, Sabina, Critchlow, Susan E., Degorce, Sébastien L., Di Fruscia, Paolo, Edmondson, Scott D., Embrey, Kevin J., Fawell, Stephen, Ghosh, Avipsa, Gill, Sonja J., Gunnarsson, Anders, Hande, Sudhir M., Heightman, Tom D., Hemsley, Paul, Illuzzi, Giuditta, Lane, Jordan, Larner, Carrie J.B., Leo, Elisabetta, Liu, Lina, Madin, Andrew, McWilliams, Lisa, O’Connor, Mark J., Orme, Jonathan P., Pachl, Fiona, Packer, Martin J., Pei, Xiaohui, Pike, Andy, Schimpl, Marianne, She, Hongyao, Staniszewska, Anna D., Talbot, Verity, Underwood, Elizabeth, Varnes, Jeffrey G., Xue, Lin, Yao, Tieguang, Zhang, Ke, Zhang, Andrew X., Zheng, Xiaolan |
| Zdroj: |
Journal of Medicinal Chemistry; December 2024, Vol. 67 Issue: 24 p21717-21728, 12p |
| Abstrakt: |
PARP inhibitors have attracted considerable interest in drug discovery due to the clinical success of first-generation agents such as olaparib, niraparib, rucaparib, and talazoparib. Their success lies in their ability to trap PARP to DNA; however, first-generation PARP inhibitors were not strictly optimized for trapping nor for selectivity among the PARP enzyme family. Previously we described the discovery of the second-generation PARP inhibitor AZD5305, a selective PARP1-DNA trapper. AZD5305 maintained the antitumor efficacy of first-generation PARP inhibitors while exhibiting lower hematological toxicity. Recently, there has been interest in central nervous system (CNS)-penetrant PARP inhibitors for CNS malignancies and other neurological conditions; however, AZD5305 is not CNS penetrant. Herein we describe the discovery and optimization of a series of CNS-penetrant, PARP1-selective inhibitors and PARP1-DNA trappers, culminating in the discovery of AZD9574, a compound that maintains the PARP1 selectivity of AZD5305 with improved permeability, reduced efflux, and increased CNS penetration. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
